Loading clinical trials...

Modified Vaccinia Ankara (MVA) Vaccine Study | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Modified Vaccinia Ankara (MVA) Vaccine Study

A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens

NCT01256853•Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed NPC, in which the presence of EBV within the malignant cells has been demonstrated by (1) EBER (EBV early RNA) in situ hybridisation in more than 50% of the malignant cells, or (2) undifferentiated or poorly differentiated carcinoma histology in association with a raised serum titer of IgA to EBV VCA.
•Patients in remission from disease, ie complete response (CR) or unconfirmed complete response (CRu).
•Completion of standard therapy for malignancy at least 12 weeks before trial entry.
•Written informed consent and the ability of the patient to co-operate with treatment and follow up must be ensured and documented.
•Age greater than 18 years.
•World Health Organisation (WHO) performance status of 0 or 1
•Life expectancy of at least 4 months.
•Haematological and biochemical indices (these measurements must be performed within 28 days prior to the patient going on study):
•* Haemoglobin (Hb) \> 10.0 g/dl
•* Lymphocytes \> 1.0 x 109/L (or above the lower limit of normal range of institutional laboratory)
+8 more criteria

Exclusion Criteria

•Receiving current chemotherapy or radiotherapy, or received within 12 weeks of trial entry.
•Known chronic active infection with Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
•Current active autoimmune disease.
•Current active skin diseases requiring therapy (psoriasis, eczema etc).
•Ongoing active infection.
•History of anaphylaxis or severe allergy to vaccination.
•Allergy to eggs or egg products.
•Previous myeloablative therapy followed by an autologous or allogeneic haematopoietic stem cell transplant.
•Patients who have had a splenectomy or splenic irradiation, or with known splenic dysfunction.
•Receiving current immunosuppressive medication, including corticosteroids.
+5 more criteria

Locations (1)

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong

Key Dates

Start Date

September 1, 2006

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

December 22, 2011

Enrollment

ACTUAL participants

Conditions

Nasopharyngeal NeoplasmsEpstein-Barr Virus Infections

Interventions

MVA Vaccine

DRUG

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT03258567

Epstein-Barr Virus InfectionsLymphoma+2 more

View study

RECRUITING

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

NCT07326358

Nasopharyngeal NeoplasmsLaryngeal Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Modified Vaccinia Ankara (MVA) Vaccine Study

Inclusion Criteria

Exclusion Criteria

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Immunodeficiency for Severe Epstein-Barr Virus Infection

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy